Search

Search results

33 results found

Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment. 2023 Jul 7;9:100212. doi: 10.1016/j.prdoa.2023.100212. eCollection 2023. PMID: 37497384

Publication: Journal Article

Isaacson, SH, RA Hauser, R Pahwa, D Gray, and S Duvvuri. 2023. “Dopamine Agonists in Parkinson’s Disease: Impact of D1-Like or D2-Like Dopamine Receptor Subtype Selectivity and Avenues for Future Treatment. 2023 Jul 7;9:100212. Doi: 10.1016/J.prdoa.2023.100212. ECollection 2023. PMID: 37497384”. Clin Park Relat Disord.

Innovation

News: September 20, 2024

The USF TTO filed a patent application for Dr. Chi and Dr. Conniff's innovative discoveries. Congratulations, Congwu and Amanda!

Long-Chain Fatty Acid Oxidation Disorders In-Clinic Disease Monitoring Program (LC-FAOD DMP)-UX007-CL401

News: September 25, 2024

Long-Chain Fatty Acid Oxidation Disorders In-Clinic Disease Monitoring Program ClinicalTrials.gov ID NCT04632953 Sponsor Ultragenyx Pharmaceutical Inc Information provided by Ultragenyx Pharmaceutical Inc (Responsible Party) Last Update Posted 2024-08-29 Study Overview The primary objective of this...

The molecular mechanism of sialic acid transport mediated by Sialin.

Publication: Journal Article

Hu, Wenxin, Congwu Chi, Kunhua Song, and Hongjin Zheng. 2023. “The Molecular Mechanism of Sialic Acid Transport Mediated by Sialin.”. Science Advances 9 (3): eade8346.

Efficacy and Safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia: ASPEN-1 Phase 3 Randomized Controlled Trial.

Publication: Journal Article

Comella, CL, J Jankovic, RA Hauser, AT Patel, MD Banach, E Ehler, D Vitarella, RG Rubio, and TM Gross. 2024. “Efficacy and Safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia: ASPEN-1 Phase 3 Randomized Controlled Trial.”. Neurology. 2024 Feb 27;102(4):e208091. Doi: 10.1212/WNL.0000000000208091. Epub 2024 Jan 31. PMID: 38295339.

Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease.

Publication: Journal Article

Frank, S, KE Anderson, HH Fernandez, RA Hauser, DO Claassen, D Stamler, SA Factor, et al. 2024. “Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated With Huntington Disease.”. Neurol Ther. 2024 Jun;13(3):655-675. Doi: 10.1007/S40120-024-00600-1. Epub 2024 Apr 1.PMID: 38557959.

Clinically important change on the Unified Dyskinesia Rating Scale among patients with Parkinson's disease experiencing dyskinesia. 2022 Oct 20;13:846126. doi: 10.3389/fneur.2022.846126. eCollection 2022. PMID: 36341088

Publication: Journal Article

Pahwa, R, S Fox, RA Hauser, S Isaacson, J Lytle, R Johnson, L Llorens, AE Formella, and CM Tanner. 2022. “Clinically Important Change on the Unified Dyskinesia Rating Scale Among Patients With Parkinson’s Disease Experiencing Dyskinesia. 2022 Oct 20;13:846126. Doi: 10.3389/Fneur.2022.846126. ECollection 2022. PMID: 36341088”. Front Neurol.

Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial. 2022 Dec;21(12):1099-1109. doi: 10.. PMID: 36402160

Publication: Journal Article

Soileau, MJ, J Aldred, K Budur, N Fisseha, VS Fung, A Jeong, TE Kimber, et al. 2022. “Safety and Efficacy of Continuous Subcutaneous Foslevodopa-Foscarbidopa in Patients With Advanced Parkinson’s Disease: a Randomised, Double-Blind, Active-Controlled, Phase 3 Trial. 2022 Dec;21(12):1099-1109. Doi: 10. PMID: 36402160”. Lancet Neurol.

Reduced Hydrogen Sulfide Bioavailability Contributes to Cardiometabolic Heart Failure with Preserved Ejection Fraction.

Publication: Journal Article

Doiron, Jake E, Mahmoud H Elbatreek, Huijing Xia, Xiaoman Yu, W H Wilson Tang, Kyle B LaPenna, Thomas E Sharp, et al. 2024. “Reduced Hydrogen Sulfide Bioavailability Contributes to Cardiometabolic Heart Failure With Preserved Ejection Fraction.”. BioRxiv : The Preprint Server for Biology.

Dr. Laura Blair was among 27 USF Faculty members to be recognized with an Outstanding Research Achievement Award

News: September 17, 2024

Dr. Laura Blair was among 27 USF Faculty members to be recognized with an Outstanding Research Achievement Award this year. She received this award for distinguished contributions to the field of neuroscience, particularly for elucidating the role of discrete molecular chaperones in the brain in the...